EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer · Source last updated 2014-11-05
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
MEAN
Unit
scores on a scale
Interval / dispersion
Standard Error
Time frame
BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
What was measured
The QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms.
Analysis population: FAS; n = number of participants assessed for a specific parameter at a given visit.
Groups in this outcome
Fluoropyrimidine/Cisplatin (FP)
Participants received fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles as follows: cisplatin 80 mg/m\^2, IV, on Day 1 and EITHER: 5-FU 800 mg/m\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\^2, tablets, PO, BID from the evening of Day 1 through the morning of Day 15.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
Participants received trastuzumab plus fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles (except as noted) as follows: trastuzumab 8 mg/kg, IV, on Day 1 (Cycle 1), followed by 6 mg/kg, IV (Cycles 2 onward, administered until disease progression); cisplatin 80 mg/m\^2 IV on Day 1; and EITHER 5-FU 800 mg/m\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\^2 tablets, PO BID from the evening of Day 1 through the morning of Day 15.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Fluoropyrimidine/Cisplatin (FP)
290
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
294
Reported measurements
Dysphagia Scale: BL (n=276,287)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
18.7
1.27
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.6
1.21
Not reported
Not reported
Not reported
Dysphagia Scale: Week 4 (n=234,250)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.8
0.92
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
12.5
1.01
Not reported
Not reported
Not reported
Dysphagia Scale: Week 7 (n=181,220)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
10.9
1.16
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
12.8
1.22
Not reported
Not reported
Not reported
Dysphagia Scale: Week 10 (n=176,203)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.5
0.97
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
10.6
1.19
Not reported
Not reported
Not reported
Dysphagia Scale: Week 13 (n=152,183)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.8
1.15
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.0
1.09
Not reported
Not reported
Not reported
Dysphagia Scale: Week 16 (n=120,165)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
10.2
1.50
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.1
1.09
Not reported
Not reported
Not reported
Dysphagia Scale: Week 19 (n=114,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
9.5
1.52
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.8
1.26
Not reported
Not reported
Not reported
Dysphagia Scale: Week 22 (n=79,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
10.0
2.11
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
7.8
1.19
Not reported
Not reported
Not reported
Dysphagia Scale: Week 25 (n=64,124)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
6.9
1.99
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.8
1.27
Not reported
Not reported
Not reported
Dysphagia Scale: Week 28 (n=47,111)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
6.6
1.84
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.3
1.03
Not reported
Not reported
Not reported
Dysphagia Scale: Week 31 (n=45,95)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
6.4
2.16
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.8
1.40
Not reported
Not reported
Not reported
Dysphagia Scale: Week 34 (n=37,87)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
3.9
1.44
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
7.5
1.51
Not reported
Not reported
Not reported
Dysphagia Scale: Week 37 (n=29,64)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
5.4
2.04
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
7.3
2.03
Not reported
Not reported
Not reported
Dysphagia Scale: Week 40 (n=24,55)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
3.7
1.59
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.5
1.82
Not reported
Not reported
Not reported
Dysphagia Scale: Week 43 (n=12,43)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
4.6
2.89
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.2
1.63
Not reported
Not reported
Not reported
Dysphagia Scale: Week 46 (n=14,42)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
2.4
1.26
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
2.9
1.08
Not reported
Not reported
Not reported
Dysphagia Scale: Week 49 (n=10,36)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
4.4
2.46
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
2.2
0.74
Not reported
Not reported
Not reported
Dysphagia Scale: Week 52 (n=8,30)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
1.4
1.39
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.4
1.81
Not reported
Not reported
Not reported
Dysphagia Scale: Week 55 (n=6,24)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
3.7
1.28
Not reported
Not reported
Not reported
Dysphagia Scale: Week 58 (n=6,21)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
3.7
2.34
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
3.2
1.56
Not reported
Not reported
Not reported
Dysphagia Scale: Week 61 (n=4,17)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
2.8
2.78
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.7
0.65
Not reported
Not reported
Not reported
Dysphagia Scale: Week 64 (n=3,20)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
3.3
1.99
Not reported
Not reported
Not reported
Dysphagia Scale: Week 67 (n=4,16)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
2.8
2.78
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
2.8
2.15
Not reported
Not reported
Not reported
Dysphagia Scale: Week 70 (n=3,14)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
3.2
2.45
Not reported
Not reported
Not reported
Dysphagia Scale: Week 73 (n=3,12)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.6
2.54
Not reported
Not reported
Not reported
Dysphagia Scale: Week 76 (n=3,8)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
2.8
1.82
Not reported
Not reported
Not reported
Dysphagia Scale: Week 79 (n=3,9)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
2.5
1.63
Not reported
Not reported
Not reported
Dysphagia Scale: Week 82 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
3.7
2.34
Not reported
Not reported
Not reported
Dysphagia Scale: Week 85 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
1.9
1.85
Not reported
Not reported
Not reported
Dysphagia Scale: Week 88 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
1.9
1.85
Not reported
Not reported
Not reported
Dysphagia Scale: Week 91 (n=2,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dysphagia Scale: Week 94 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
1.9
1.85
Not reported
Not reported
Not reported
Dysphagia Scale: Week 97 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
2.2
2.22
Not reported
Not reported
Not reported
Dysphagia Scale: Week 100 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
2.8
2.78
Not reported
Not reported
Not reported
Dysphagia Scale: Week 103 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dysphagia Scale: Week 106 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dysphagia Scale: Week 109 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dysphagia Scale: Week 112 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dysphagia Scale: Week 115 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dysphagia Scale: Week 118 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
2.2
2.22
Not reported
Not reported
Not reported
Dysphagia Scale: Week 121 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dysphagia Scale: Week 124 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dysphagia Scale: Week 127 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dysphagia Scale: Week 130 (n=0,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dysphagia Scale: Week 133 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dysphagia Scale: Week 136 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dysphagia Scale: Week 139 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.6
5.56
Not reported
Not reported
Not reported
Dysphagia Scale: Week 142 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.6
5.56
Not reported
Not reported
Not reported
Dysphagia Scale: Week 145 (n=0,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Dysphagia Scale: Final Visit (n=157,159
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
15.4
1.77
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
17.0
1.92
Not reported
Not reported
Not reported
Pain Scale: BL (n=276,287)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
29.7
1.32
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
27.0
1.20
Not reported
Not reported
Not reported
Pain Scale: Week 4 (n=234,250)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
21.6
1.15
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
21.8
1.05
Not reported
Not reported
Not reported
Pain Scale: Week 7 (n=181,219)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
19.4
1.26
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
20.1
1.30
Not reported
Not reported
Not reported
Pain Scale: Week 10 (n=176,203)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
17.0
1.11
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
17.5
1.14
Not reported
Not reported
Not reported
Pain Scale: Week 13 (n=152,183)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
16.0
1.25
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.2
1.21
Not reported
Not reported
Not reported
Pain Scale: Week 16 (n=120,165)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
17.0
1.45
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
15.9
1.23
Not reported
Not reported
Not reported
Pain Scale: Week 19 (n=114,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
19.2
1.95
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.3
1.32
Not reported
Not reported
Not reported
Pain Scale: Week 22 (n=79,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
15.8
2.05
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
15.1
1.58
Not reported
Not reported
Not reported
Pain Scale: Week 25 (n=64,124)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.3
1.82
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
14.4
1.63
Not reported
Not reported
Not reported
Pain Scale: Week 28 (n=47,111)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.2
1.95
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
14.0
1.64
Not reported
Not reported
Not reported
Pain Scale: Week 31 (n=45,95)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
12.6
2.33
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
14.6
2.09
Not reported
Not reported
Not reported
Pain Scale: Week 34 (n=37,87)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
12.2
2.18
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
12.5
2.04
Not reported
Not reported
Not reported
Pain Scale: Week 37 (n=29,64)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
13.8
2.90
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
13.8
2.63
Not reported
Not reported
Not reported
Pain Scale: Week 40 (n=24,55)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
14.9
2.97
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
11.8
2.28
Not reported
Not reported
Not reported
Pain Scale: Week 43 (n=12,43)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
13.0
3.41
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.7
1.98
Not reported
Not reported
Not reported
Pain Scale: Week 46 (n=14,42)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
15.5
3.13
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
10.1
2.35
Not reported
Not reported
Not reported
Pain Scale: Week 49 (n=10,36)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.7
4.51
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.5
1.79
Not reported
Not reported
Not reported
Pain Scale: Week 52 (n=8,30)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
9.4
4.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.6
2.69
Not reported
Not reported
Not reported
Pain Scale: Week 55 (n=6,24)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
9.7
5.01
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.5
1.42
Not reported
Not reported
Not reported
Pain Scale: Week 58 (n=6,21)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
5.6
4.12
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.3
1.90
Not reported
Not reported
Not reported
Pain Scale: Week 61 (n=4,17)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
4.2
2.41
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.4
2.36
Not reported
Not reported
Not reported
Pain Scale: Week 64 (n=3,20)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
2.8
2.78
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.6
2.28
Not reported
Not reported
Not reported
Pain Scale: Week 67 (n=4,16)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
4.2
4.17
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
2.95
Not reported
Not reported
Not reported
Pain Scale: Week 70 (n=3,14)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
2.8
2.78
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.5
2.17
Not reported
Not reported
Not reported
Pain Scale: Week 73 (n=3,12)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.7
3.95
Not reported
Not reported
Not reported
Pain Scale: Week 76 (n=3,8)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
5.6
5.56
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.2
2.19
Not reported
Not reported
Not reported
Pain Scale: Week 79 (n=3,9)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
2.8
2.78
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
7.4
3.79
Not reported
Not reported
Not reported
Pain Scale: Week 82 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.9
3.98
Not reported
Not reported
Not reported
Pain Scale: Week 85 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
4.2
4.17
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.6
4.12
Not reported
Not reported
Not reported
Pain Scale: Week 88 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.3
8.33
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.6
2.78
Not reported
Not reported
Not reported
Pain Scale: Week 91 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
2.1
2.08
Not reported
Not reported
Not reported
Pain Scale: Week 94 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.6
3.51
Not reported
Not reported
Not reported
Pain Scale: Week 97 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
3.73
Not reported
Not reported
Not reported
Pain Scale: Week 100 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.3
2.08
Not reported
Not reported
Not reported
Pain Scale: Week 103 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
3.40
Not reported
Not reported
Not reported
Pain Scale: Week 106 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.3
3.99
Not reported
Not reported
Not reported
Pain Scale: Week 109 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.2
2.41
Not reported
Not reported
Not reported
Pain Scale: Week 112 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
10.0
4.86
Not reported
Not reported
Not reported
Pain Scale: Week 115 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.2
2.41
Not reported
Not reported
Not reported
Pain Scale: Week 118 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
3.73
Not reported
Not reported
Not reported
Pain Scale: Week 121 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
10.0
4.86
Not reported
Not reported
Not reported
Pain Scale: Week 124 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
3.73
Not reported
Not reported
Not reported
Pain Scale: Week 127 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
8.33
Not reported
Not reported
Not reported
Pain Scale: Week 130 (n=0,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
11.1
7.35
Not reported
Not reported
Not reported
Pain Scale: Week 133 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
13.9
7.35
Not reported
Not reported
Not reported
Pain Scale: Week 136 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
12.5
4.17
Not reported
Not reported
Not reported
Pain Scale: Week 139 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
8.33
Not reported
Not reported
Not reported
Pain Scale: Week 142 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
0.00
Not reported
Not reported
Not reported
Pain Scale: Week 145 (n=0,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Pain Scale: Final Visit (n=157,160)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
24.7
1.60
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
26.8
2.02
Not reported
Not reported
Not reported
Reflux Symptoms Scale: BL (n=275,287)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
18.3
1.29
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.9
1.12
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 4 (n=234,250)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
14.8
1.14
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.0
1.09
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 7 (n=180,220)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
12.8
1.26
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
15.4
1.20
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 10 (n=176,203)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
12.6
1.29
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
13.5
1.18
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 13 (n=152,182)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
12.8
1.39
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
12.9
1.34
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 16 (n=120,165)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
12.0
1.55
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
14.4
1.58
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 19 (n=114,165)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.3
1.76
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
10.6
1.24
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 22 (n=79,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
9.0
1.79
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
10.6
1.37
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 25 (n=64,124)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
5.6
1.21
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.7
1.34
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 28 (n=47,111)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
6.6
1.61
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.6
1.42
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 31 (n=45,95)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
7.4
1.69
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
10.1
1.93
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 34 (n=45,95)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
7.2
2.16
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.3
1.77
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 37 (n=29,64)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
6.1
1.62
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
10.9
2.38
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 40 (n=24,55)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
7.9
2.80
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.3
2.13
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 43 (n=12,42)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
7.4
3.44
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.0
2.07
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 46 (n=14,42)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
4.8
1.53
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.6
1.97
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 49 (n=10,36)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
2.2
1.48
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.5
1.43
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 52 (n=8,30)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
2.8
1.82
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.1
2.55
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 55 (n=6,24)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
5.6
5.56
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.5
2.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 58 (n=6,21)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.3
1.65
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 61 (n=4,17)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
2.8
2.78
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
2.6
1.52
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 64 (n=3,20)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
3.7
3.70
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
3.9
1.85
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 67 (n=4,16)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
2.8
2.78
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.3
2.48
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 70 (n=3,13)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
3.7
3.70
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.3
2.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 73 (n=3,12)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
7.9
2.60
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 76 (n=3,8)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
3.7
3.70
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
1.4
1.39
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 79 (n=3,9)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
3.7
2.62
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 82 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.6
2.48
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 85 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 88 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 91 (n=2,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 94 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 97 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 100 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 103 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 106 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
2.8
2.78
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 109 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 112 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 115 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 118 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.4
4.44
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 121 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 124 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.7
4.44
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 127 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
7.4
7.41
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 130 (n=0,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 133 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 136 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 139 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 142 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Reflux Symptoms Scale: Week 145 (n=0,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Reflux Symptoms Scale: Final Visit (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
15.3
1.48
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
18.3
1.72
Not reported
Not reported
Not reported
Eating Restrictions (ER) Scale: BL (n=276,287)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
27.4
1.44
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
23.9
1.30
Not reported
Not reported
Not reported
ER Scale: Week 4 (n=234,250)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
20.6
1.24
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
21.1
1.19
Not reported
Not reported
Not reported
ER Scale: Week 7 (n=181,220)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
18.8
1.36
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
19.0
1.26
Not reported
Not reported
Not reported
ER Scale: Week 10 (n=176,203)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
17.5
1.25
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
17.4
1.23
Not reported
Not reported
Not reported
ER Scale: Week 13 (n=152,183)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
16.0
1.77
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
17.0
1.34
Not reported
Not reported
Not reported
ER Scale: Week 16 (n=120,165)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
17.8
1.77
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
15.1
1.40
Not reported
Not reported
Not reported
ER Scale: Week 19 (n=114,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
20.8
2.01
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
15.5
1.53
Not reported
Not reported
Not reported
ER Scale: Week 22 (n=79,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
15.5
2.14
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
13.6
1.56
Not reported
Not reported
Not reported
ER Scale: Week 25 (n=64,124)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.6
2.14
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
12.9
1.39
Not reported
Not reported
Not reported
ER Scale: Week 28 (n=47,111)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
13.9
2.64
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
11.3
1.37
Not reported
Not reported
Not reported
ER Scale: Week 31 (n=45,95)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
13.4
2.69
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
12.5
2.03
Not reported
Not reported
Not reported
ER Scale: Week 34 (n=37,87)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
10.6
2.16
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
10.9
1.90
Not reported
Not reported
Not reported
ER Scale: Week 37 (n=29,64)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
12.5
3.10
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.5
2.11
Not reported
Not reported
Not reported
ER Scale: Week 40 (n=24,55)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
13.5
3.32
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.5
2.21
Not reported
Not reported
Not reported
ER Scale: Week 43 (n=12,43)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
9.7
3.22
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
7.0
1.88
Not reported
Not reported
Not reported
ER Scale: Week 46 (n=14,42)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
10.9
3.07
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.0
1.31
Not reported
Not reported
Not reported
ER Scale: Week 49 (n=10,36)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.7
3.09
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.1
1.83
Not reported
Not reported
Not reported
ER Scale: Week 52 (n=8,30)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
5.2
2.19
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.3
2.31
Not reported
Not reported
Not reported
ER Scale: Week 55 (n=6,24)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.3
4.30
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.2
1.86
Not reported
Not reported
Not reported
ER Scale: Week 58 (n=6,21)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
9.7
5.45
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.0
2.31
Not reported
Not reported
Not reported
ER Scale: Week 61 (n=4,17)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
4.2
2.41
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.4
2.01
Not reported
Not reported
Not reported
ER Scale: Week 64 (n=3,20)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
2.42
Not reported
Not reported
Not reported
ER Scale: Week 67 (n=4,16)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.3
4.81
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
10.4
3.36
Not reported
Not reported
Not reported
ER Scale: Week 70 (n=3,14)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
2.8
2.78
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.5
2.34
Not reported
Not reported
Not reported
ER Scale: Week 73 (n=3,12)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
5.6
5.56
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.0
3.32
Not reported
Not reported
Not reported
ER Scale: Week 76 (n=3,8)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
2.8
2.78
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.2
3.50
Not reported
Not reported
Not reported
ER Scale: Week 79 (n=3,9)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
5.6
5.56
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.6
3.11
Not reported
Not reported
Not reported
ER Scale: Week 82 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
4.2
4.17
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
2.8
2.78
Not reported
Not reported
Not reported
ER Scale: Week 85 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
4.2
4.17
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.2
2.85
Not reported
Not reported
Not reported
ER Scale: Week 88 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
4.2
4.17
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.2
1.86
Not reported
Not reported
Not reported
ER Scale: Week 91 (n=2,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.3
8.33
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.2
4.17
Not reported
Not reported
Not reported
ER Scale: Week 94 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.2
2.85
Not reported
Not reported
Not reported
ER Scale: Week 97 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.7
3.12
Not reported
Not reported
Not reported
ER Scale: Week 100 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.3
3.99
Not reported
Not reported
Not reported
ER Scale: Week 103 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.3
3.99
Not reported
Not reported
Not reported
ER Scale: Week 106 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.2
4.17
Not reported
Not reported
Not reported
ER Scale: Week 109 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.2
4.17
Not reported
Not reported
Not reported
ER Scale: Week 112 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
3.3
3.33
Not reported
Not reported
Not reported
ER Scale: Week 115 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.2
4.17
Not reported
Not reported
Not reported
ER Scale: Week 118 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.7
3.12
Not reported
Not reported
Not reported
ER Scale: Week 121 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.0
3.33
Not reported
Not reported
Not reported
ER Scale: Week 124 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
1.7
1.67
Not reported
Not reported
Not reported
ER Scale: Week 127 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
ER Scale: Week 130 (n=0,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
4.81
Not reported
Not reported
Not reported
ER Scale: Week 133 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.6
2.78
Not reported
Not reported
Not reported
ER Scale: Week 136 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
ER Scale: Week 139 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.2
4.17
Not reported
Not reported
Not reported
ER Scale: Week 142 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
ER Scale: Week 145 (n=0,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
ER Scale: Final Visit (n=157,160)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
23.8
1.85
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
22.8
1.84
Not reported
Not reported
Not reported
Anxiety Scale: BL (n=276,287)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
47.5
1.66
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
48.2
1.54
Not reported
Not reported
Not reported
Anxiety Scale: Week 4 (n=234,250)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
42.0
1.66
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
43.8
1.60
Not reported
Not reported
Not reported
Anxiety Scale: Week 7 (n=181,220)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
40.6
1.77
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
39.3
1.66
Not reported
Not reported
Not reported
Anxiety Scale: Week 10 (n=176,203)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
38.2
1.98
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
38.2
1.70
Not reported
Not reported
Not reported
Anxiety Scale: Week 13 (n=152,183)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
35.7
2.01
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
37.5
1.99
Not reported
Not reported
Not reported
Anxiety Scale: Week 16 (n=120,165)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
32.9
2.27
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
37.1
2.10
Not reported
Not reported
Not reported
Anxiety Scale: Week 19 (n=114,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
35.8
2.40
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
34.9
2.04
Not reported
Not reported
Not reported
Anxiety Scale: Week 22 (n=79,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
31.7
3.16
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
32.8
2.05
Not reported
Not reported
Not reported
Anxiety Scale: Week 25 (n=64,124)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
25.2
2.86
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
29.2
2.03
Not reported
Not reported
Not reported
Anxiety Scale: Week 28 (n=47,111)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
27.4
3.65
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
26.9
1.88
Not reported
Not reported
Not reported
Anxiety Scale: Week 31 (n=45,95)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
29.1
4.36
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
28.4
2.32
Not reported
Not reported
Not reported
Anxiety Scale: Week 34 (n=37,87)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
23.1
3.69
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
27.8
2.33
Not reported
Not reported
Not reported
Anxiety Scale: Week 37 (n=29,64)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
27.2
4.79
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
28.2
2.87
Not reported
Not reported
Not reported
Anxiety Scale: Week 40 (n=24,55)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
29.6
3.99
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
26.3
2.77
Not reported
Not reported
Not reported
Anxiety Scale: Week 43 (n=12,43)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
30.6
7.63
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
25.1
2.91
Not reported
Not reported
Not reported
Anxiety Scale: Week 46 (n=14,42)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
26.2
6.34
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
23.3
3.00
Not reported
Not reported
Not reported
Anxiety Scale: Week 49 (n=14,42)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
20.0
7.55
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
25.9
3.03
Not reported
Not reported
Not reported
Anxiety Scale: Week 52 (n=8,30)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
23.6
7.98
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
27.4
4.15
Not reported
Not reported
Not reported
Anxiety Scale: Week 55 (n=6,24)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
31.5
12.31
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
28.2
3.90
Not reported
Not reported
Not reported
Anxiety Scale: Week 58 (n=6,21)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
20.4
10.11
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
21.7
3.38
Not reported
Not reported
Not reported
Anxiety Scale: Week 61 (n=4,17)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.3
5.32
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
25.5
5.37
Not reported
Not reported
Not reported
Anxiety Scale: Week 64 (n=3,20)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
5.6
5.56
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
23.9
4.21
Not reported
Not reported
Not reported
Anxiety Scale: Week 67 (n=4,16)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.1
6.42
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
18.8
3.47
Not reported
Not reported
Not reported
Anxiety Scale: Week 70 (n=3,14)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
3.7
3.70
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
27.0
5.91
Not reported
Not reported
Not reported
Anxiety Scale: Week 73 (n=3,12)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
7.4
7.41
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
28.7
6.03
Not reported
Not reported
Not reported
Anxiety Scale: Week 76 (n=3,8)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
27.8
8.13
Not reported
Not reported
Not reported
Anxiety Scale: Week 79 (n=3,9)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.1
11.11
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
33.3
8.28
Not reported
Not reported
Not reported
Anxiety Scale: Week 82 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.1
11.11
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
25.9
8.92
Not reported
Not reported
Not reported
Anxiety Scale: Week 85 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.1
11.11
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
24.1
3.41
Not reported
Not reported
Not reported
Anxiety Scale: Week 88 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.1
11.11
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
14.8
5.49
Not reported
Not reported
Not reported
Anxiety Scale: Week 91 (n=2,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.1
11.11
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
22.2
4.54
Not reported
Not reported
Not reported
Anxiety Scale: Week 94 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
5.6
5.56
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
22.2
2.87
Not reported
Not reported
Not reported
Anxiety Scale: Week 97 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
31.1
5.44
Not reported
Not reported
Not reported
Anxiety Scale: Week 100 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
5.56
Not reported
Not reported
Not reported
Anxiety Scale: Week 103 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
22.2
4.54
Not reported
Not reported
Not reported
Anxiety Scale: Week 106 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
19.4
5.32
Not reported
Not reported
Not reported
Anxiety Scale: Week 109 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
7.17
Not reported
Not reported
Not reported
Anxiety Scale: Week 112 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
22.2
4.97
Not reported
Not reported
Not reported
Anxiety Scale: Week 115 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
19.4
8.33
Not reported
Not reported
Not reported
Anxiety Scale: Week 118 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
20.0
6.48
Not reported
Not reported
Not reported
Anxiety Scale: Week 121 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
15.6
7.54
Not reported
Not reported
Not reported
Anxiety Scale: Week 124 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
17.8
5.67
Not reported
Not reported
Not reported
Anxiety Scale: Week 127 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
22.2
11.11
Not reported
Not reported
Not reported
Anxiety Scale: Week 130 (n=0,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
18.5
9.80
Not reported
Not reported
Not reported
Anxiety Scale: Week 133 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
18.5
9.80
Not reported
Not reported
Not reported
Anxiety Scale: Week 136 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
16.67
Not reported
Not reported
Not reported
Anxiety Scale: Week 139 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
11.1
11.11
Not reported
Not reported
Not reported
Anxiety Scale: Week 142 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
16.67
Not reported
Not reported
Not reported
Anxiety Scale: Week 145 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Anxiety Scale: Final Visit (n=157,160)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
41.5
2.19
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
40.9
2.22
Not reported
Not reported
Not reported
Dry Mouth: BL (n=274,287)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
24.5
1.70
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
23.9
1.70
Not reported
Not reported
Not reported
Dry Mouth: Week 4 (n=232,249)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
24.0
1.81
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
23.3
1.59
Not reported
Not reported
Not reported
Dry Mouth: Week 7 (n=180,219)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
24.6
2.02
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
26.9
1.87
Not reported
Not reported
Not reported
Dry Mouth: Week 10 (n=176,203)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
23.5
1.85
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
25.0
1.96
Not reported
Not reported
Not reported
Dry Mouth: Week 13 (n=152,183)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
23.2
2.06
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
21.1
1.95
Not reported
Not reported
Not reported
Dry Mouth: Week 16 (n=120,165)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
23.9
2.41
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
23.4
2.19
Not reported
Not reported
Not reported
Dry Mouth: Week 19 (n=113,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
22.4
2.56
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
20.5
2.17
Not reported
Not reported
Not reported
Dry Mouth: Week 22 (n=79,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
19.0
2.92
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.3
2.06
Not reported
Not reported
Not reported
Dry Mouth: Week 25 (n=64,124)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
16.1
3.06
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
12.1
1.80
Not reported
Not reported
Not reported
Dry Mouth: Week 28 (n=47,111)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
10.6
2.51
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
10.8
1.55
Not reported
Not reported
Not reported
Dry Mouth: Week 31 (n=45,95)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
12.6
3.23
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
11.2
2.21
Not reported
Not reported
Not reported
Dry Mouth: Week 34 (n=37,87)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
9.9
3.38
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.6
1.88
Not reported
Not reported
Not reported
Dry Mouth: Week 37 (n=29,64)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
12.6
4.19
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.4
2.28
Not reported
Not reported
Not reported
Dry Mouth: Week 40 (n=23,55)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.7
3.76
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
7.3
2.40
Not reported
Not reported
Not reported
Dry Mouth: Week 43 (n=12,43)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.1
4.74
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.2
2.00
Not reported
Not reported
Not reported
Dry Mouth: Week 46 (n=14,42)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
9.5
4.18
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.8
1.82
Not reported
Not reported
Not reported
Dry Mouth: Week 49 (n=10,36)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
16.7
5.56
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.5
2.23
Not reported
Not reported
Not reported
Dry Mouth: Week 52 (n=8,30)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
12.5
6.10
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
10.0
3.26
Not reported
Not reported
Not reported
Dry Mouth: Week 55 (n=6,24)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
5.6
5.56
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
3.01
Not reported
Not reported
Not reported
Dry Mouth: Week 58 (n=6,21)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.1
7.03
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
14.3
4.35
Not reported
Not reported
Not reported
Dry Mouth: Week 61 (n=4,17)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.3
8.33
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
11.8
4.90
Not reported
Not reported
Not reported
Dry Mouth: Week 64 (n=3,20)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.7
3.06
Not reported
Not reported
Not reported
Dry Mouth: Week 67 (n=4,16)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.3
8.33
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
4.81
Not reported
Not reported
Not reported
Dry Mouth: Week 70 (n=3,14)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
11.9
5.64
Not reported
Not reported
Not reported
Dry Mouth: Week 73 (n=3,12)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
13.9
4.95
Not reported
Not reported
Not reported
Dry Mouth: Week 76 (n=3,8)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
20.8
8.77
Not reported
Not reported
Not reported
Dry Mouth: Week 79 (n=3,9)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
11.1
5.56
Not reported
Not reported
Not reported
Dry Mouth: Week 82 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.6
5.56
Not reported
Not reported
Not reported
Dry Mouth: Week 85 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
16.7
16.67
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 88 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.6
5.56
Not reported
Not reported
Not reported
Dry Mouth: Week 91 (n=2,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 94 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 97 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 100 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 103 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.0
Not reported
Not reported
Not reported
Dry Mouth: Week 106 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 109 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 112 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 115 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 118 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 121 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 124 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 127 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 130 (n=0,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 133 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 136 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 139 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 142 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Dry Mouth: Week 145 (n=0,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Dry Mouth: Final Visit (n=157,157)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
24.0
2.52
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
23.6
2.43
Not reported
Not reported
Not reported
Taste: BL (n=275,286)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
17.2
1.56
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
17.9
1.64
Not reported
Not reported
Not reported
Taste: Week 4 (n=234,249)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
20.7
1.63
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
24.8
1.79
Not reported
Not reported
Not reported
Taste: Week 7 (n=179,217)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
20.1
1.78
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
24.0
1.85
Not reported
Not reported
Not reported
Taste: Week 10 (n=176,200)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
21.8
1.86
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
25.3
2.01
Not reported
Not reported
Not reported
Taste: Week 13 (n=151,181)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
19.9
2.08
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
25.2
2.20
Not reported
Not reported
Not reported
Taste: Week 16 (n=119,165)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
20.4
2.22
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
23.8
2.23
Not reported
Not reported
Not reported
Taste: Week 19 (n=113,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
24.5
2.37
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
22.6
2.26
Not reported
Not reported
Not reported
Taste: Week 22 (n=79,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
19.0
2.86
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
19.6
2.15
Not reported
Not reported
Not reported
Taste: Week 25 (n=64,124)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
10.9
2.23
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
15.9
1.96
Not reported
Not reported
Not reported
Taste: Week 28 (n=47,111)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
12.1
2.76
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
14.7
2.03
Not reported
Not reported
Not reported
Taste: Week 31 (n=45,95)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.1
2.63
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
13.0
2.65
Not reported
Not reported
Not reported
Taste: Week 34 (n=37,87)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
6.3
2.53
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.6
2.10
Not reported
Not reported
Not reported
Taste: Week 37 (n=28,64)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.3
3.26
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
7.8
2.20
Not reported
Not reported
Not reported
Taste: Week 40 (n=24,55)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.3
3.01
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
7.9
2.73
Not reported
Not reported
Not reported
Taste: Week 43 (n=12,43)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
5.6
3.75
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
7.0
2.09
Not reported
Not reported
Not reported
Taste: Week 46 (n=14,42)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
4.8
3.24
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
7.9
2.74
Not reported
Not reported
Not reported
Taste: Week 49 (n=9,36)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
7.4
4.90
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.6
1.95
Not reported
Not reported
Not reported
Taste: Week 52 (n=8,30)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
4.2
4.17
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
7.8
3.46
Not reported
Not reported
Not reported
Taste: Week 55 (n=6,24)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.1
7.03
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.2
2.30
Not reported
Not reported
Not reported
Taste: Week 58 (n=6,21)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.1
7.03
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.8
2.61
Not reported
Not reported
Not reported
Taste: Week 61 (n=4,17)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.3
8.33
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 64 (n=3,20)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.1
11.11
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
1.7
1.67
Not reported
Not reported
Not reported
Taste: Week 67 (n=4,16)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.3
8.33
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
4.2
2.85
Not reported
Not reported
Not reported
Taste: Week 70 (n=3,14)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 73 (n=3,12)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
2.8
2.78
Not reported
Not reported
Not reported
Taste: Week 76 (n=3,8)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 79 (n=3,9)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 82 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.6
5.56
Not reported
Not reported
Not reported
Taste: Week 85 (n=2, 6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 88 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.6
5.56
Not reported
Not reported
Not reported
Taste: Week 91 (n=2,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 94 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.6
5.56
Not reported
Not reported
Not reported
Taste: Week 97 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.7
6.67
Not reported
Not reported
Not reported
Taste: Week 100 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 103 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 106 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 109 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 112 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 115 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 118 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 121 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 124 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 127 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 130 (n=0,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 133 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 136 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 139 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 142 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Taste: Week 145 (n=0,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Taste: Final Visit (n=157,158)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
25.3
2.26
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
20.3
2.28
Not reported
Not reported
Not reported
Body Image: BL (n=272,286)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
30.9
1.95
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
31.9
1.93
Not reported
Not reported
Not reported
Body Image: Week 4 (n=233,249)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
32.6
2.10
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
31.7
2.03
Not reported
Not reported
Not reported
Body Image: Week 7 (n=180,219)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
30.7
2.19
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
27.9
1.94
Not reported
Not reported
Not reported
Body Image: Week 10 (n=175,203)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
30.1
2.27
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
28.4
2.05
Not reported
Not reported
Not reported
Body Image: Week 13 (n=152,182)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
28.9
2.54
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
28.2
2.36
Not reported
Not reported
Not reported
Body Image: Week 16 (n=119,165)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
29.1
2.69
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
28.1
2.29
Not reported
Not reported
Not reported
Body Image: Week 19 (n=114,140)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
30.7
2.82
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
25.0
2.53
Not reported
Not reported
Not reported
Body Image: Week 22 (n=79,143)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
28.7
3.59
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
22.4
2.29
Not reported
Not reported
Not reported
Body Image: Week 25 (n=64,124)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
22.4
3.32
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
22.6
2.60
Not reported
Not reported
Not reported
Body Image: Week 28 (n=47,111)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
23.4
4.41
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
20.1
2.53
Not reported
Not reported
Not reported
Body Image: Week 31 (n=45,95)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
25.2
4.87
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
19.3
2.80
Not reported
Not reported
Not reported
Body Image: Week 34 (n=37,87)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
18.9
4.75
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
18.0
2.66
Not reported
Not reported
Not reported
Body Image: Week 37 (n=29,64)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
23.0
5.99
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
18.2
3.48
Not reported
Not reported
Not reported
Body Image: Week 40 (n=24,55)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
20.8
5.96
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
19.4
3.53
Not reported
Not reported
Not reported
Body Image: Week 43 (n=12,43)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
27.8
6.91
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
15.5
3.90
Not reported
Not reported
Not reported
Body Image: Week 46 (n=14,42)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
21.4
6.64
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
15.9
3.81
Not reported
Not reported
Not reported
Body Image: Week 49 (n=10,36)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
16.7
7.45
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
13.9
4.07
Not reported
Not reported
Not reported
Body Image: Week 52 (n=8,30)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
16.7
8.91
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
3.83
Not reported
Not reported
Not reported
Body Image: Week 55 (n=6,24)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
16.7
11.39
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
4.91
Not reported
Not reported
Not reported
Body Image: Week 58 (n=6,21)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.1
7.03
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
15.9
5.45
Not reported
Not reported
Not reported
Body Image: Week 61 (n=4,17)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.3
8.33
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
13.7
5.76
Not reported
Not reported
Not reported
Body Image: Week 64 (n=3,20)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
18.3
4.51
Not reported
Not reported
Not reported
Body Image: Week 67 (n=4,16)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
14.6
4.27
Not reported
Not reported
Not reported
Body Image: Week 70 (n=4,14)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
5.79
Not reported
Not reported
Not reported
Body Image: Week 73 (n=3,12)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
27.8
9.02
Not reported
Not reported
Not reported
Body Image: Week 76 (n=3,8)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
37.5
11.68
Not reported
Not reported
Not reported
Body Image: Week 79 (n=3,9)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
25.9
9.26
Not reported
Not reported
Not reported
Body Image: Week 82 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
7.45
Not reported
Not reported
Not reported
Body Image: Week 85 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
11.1
7.03
Not reported
Not reported
Not reported
Body Image: Week 88 (n=2,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.7
6.67
Not reported
Not reported
Not reported
Body Image: Week 91 (n=2,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
9.62
Not reported
Not reported
Not reported
Body Image: Week 94 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
7.45
Not reported
Not reported
Not reported
Body Image: Week 97 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
13.3
8.16
Not reported
Not reported
Not reported
Body Image: Week 100 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
8.33
Not reported
Not reported
Not reported
Body Image: Week 103 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
8.33
Not reported
Not reported
Not reported
Body Image: Week 106 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
9.62
Not reported
Not reported
Not reported
Body Image: Week 109 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
8.33
Not reported
Not reported
Not reported
Body Image: Week 112 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.7
6.67
Not reported
Not reported
Not reported
Body Image: Week 115 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
9.62
Not reported
Not reported
Not reported
Body Image: Week 118 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.7
6.67
Not reported
Not reported
Not reported
Body Image: Week 121 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.7
6.67
Not reported
Not reported
Not reported
Body Image: Week 124 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.67
6.67
Not reported
Not reported
Not reported
Body Image: Week 127 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
11.1
11.11
Not reported
Not reported
Not reported
Body Image: Week 130 (n=0,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Body Image: Week 133 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
11.1
11.11
Not reported
Not reported
Not reported
Body Image: Week 136 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
16.67
Not reported
Not reported
Not reported
Body Image: Week 139 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Body Image: Week 142 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
16.67
Not reported
Not reported
Not reported
Body Image: Week 145 (n=0,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Body Image: Final Visit (n=157,159)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
31.0
2.58
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
30.4
2.42
Not reported
Not reported
Not reported
Hair Loss: BL (n=64,76)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
15.1
3.31
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
25.0
3.80
Not reported
Not reported
Not reported
Hair Loss: Week 4 (n=68,71)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
20.1
3.43
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.4
2.90
Not reported
Not reported
Not reported
Hair Loss: Week 7 (n=65,82)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
25.1
3.27
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
19.1
3.01
Not reported
Not reported
Not reported
Hair Loss: Week 10 (n=75,78)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
21.8
3.07
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
20.1
2.81
Not reported
Not reported
Not reported
Hair Loss: Week 13 (n=66,80)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
22.2
3.40
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
20.4
3.05
Not reported
Not reported
Not reported
Hair Loss: Week 16 (n=53,72)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
28.3
4.34
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
23.6
3.26
Not reported
Not reported
Not reported
Hair Loss: Week 19 (n=50,56)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
23.3
4.29
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
21.4
3.55
Not reported
Not reported
Not reported
Hair Loss: Week 22 (n=38,54)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
20.2
4.45
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
22.2
3.52
Not reported
Not reported
Not reported
Hair Loss: Week 25 (n=24,49)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
13.9
4.88
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
18.4
3.64
Not reported
Not reported
Not reported
Hair Loss: Week 28 (n=20,39)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
26.7
7.87
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
14.5
4.38
Not reported
Not reported
Not reported
Hair Loss: Week 31 (n=17,26)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
15.7
7.07
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
10.3
4.44
Not reported
Not reported
Not reported
Hair Loss: Week 34 (n=13,24)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
7.7
5.54
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
5.68
Not reported
Not reported
Not reported
Hair Loss: Week 37 (n=12,16)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
8.3
5.98
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
12.5
4.17
Not reported
Not reported
Not reported
Hair Loss: Week 40 (n=11,13)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
12.1
6.78
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
12.8
6.01
Not reported
Not reported
Not reported
Hair Loss: Week 43 (n=5,9)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
6.7
6.67
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
3.7
3.70
Not reported
Not reported
Not reported
Hair Loss: Week 46 (n=5,13)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
26.7
19.44
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
5.1
3.47
Not reported
Not reported
Not reported
Hair Loss: Week 49 (n=4,7)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
0.00
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
9.5
6.15
Not reported
Not reported
Not reported
Hair Loss: Week 52 (n=3,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
11.1
11.11
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
8.3
8.33
Not reported
Not reported
Not reported
Hair Loss: Week 55 (n=2,6)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
16.7
16.67
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 58 (n=2,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
16.7
16.67
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 61 (n=1,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
16.7
16.67
Not reported
Not reported
Not reported
Hair Loss: Week 64 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 67 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 70 (n=1,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 73 (n=1,5)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
6.7
6.67
Not reported
Not reported
Not reported
Hair Loss: Week 76 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 79 (n=1,4)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 82 (n=1,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Hair Loss: Week 85 (n=1,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Hair Loss: Week 88 (n=1,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 91 (n=1,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Hair Loss: Week 94 (n=1,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 97 (n=1,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 100 (n=1,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 103 (n=1,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Hair Loss: Week 106 (n=1,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Hair Loss: Week 109 (n=0,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 112 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 115 (n=1,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 118 (n=1,3)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 121 (n=1,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 124 (n=1,2)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
0.00
Not reported
Not reported
Not reported
Hair Loss: Week 127 (n=1,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Hair Loss: Week 130 (n=0,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
NA
NA
Not reported
Not reported
No participants were analyzed in this treatment group for this timepoint.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Hair Loss: Week 133 (n=1,1)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
0.0
NA
Not reported
Not reported
Only 1 participant was analyzed in this treatment group at this timepoint, therefore standard error of the mean could not be calculated.
Hair Loss: Final Visit (n=61,60)
Values in scores on a scale · Interval/dispersion: Standard Error
Group
Value
Spread
Lower
Upper
Comment
Fluoropyrimidine/Cisplatin (FP)
23.0
3.62
Not reported
Not reported
Not reported
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
19.4
3.29
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
spread
1.27
value
18.7
group Id
OG001
spread
1.21
value
16.6
title
Dysphagia Scale: BL (n=276,287)
categories
measurements
group Id
OG000
spread
0.92
value
11.8
group Id
OG001
spread
1.01
value
12.5
title
Dysphagia Scale: Week 4 (n=234,250)
categories
measurements
group Id
OG000
spread
1.16
value
10.9
group Id
OG001
spread
1.22
value
12.8
title
Dysphagia Scale: Week 7 (n=181,220)
categories
measurements
group Id
OG000
spread
0.97
value
8.5
group Id
OG001
spread
1.19
value
10.6
title
Dysphagia Scale: Week 10 (n=176,203)
categories
measurements
group Id
OG000
spread
1.15
value
8.8
group Id
OG001
spread
1.09
value
9.0
title
Dysphagia Scale: Week 13 (n=152,183)
categories
measurements
group Id
OG000
spread
1.50
value
10.2
group Id
OG001
spread
1.09
value
9.1
title
Dysphagia Scale: Week 16 (n=120,165)
categories
measurements
group Id
OG000
spread
1.52
value
9.5
group Id
OG001
spread
1.26
value
8.8
title
Dysphagia Scale: Week 19 (n=114,143)
categories
measurements
group Id
OG000
spread
2.11
value
10.0
group Id
OG001
spread
1.19
value
7.8
title
Dysphagia Scale: Week 22 (n=79,143)
categories
measurements
group Id
OG000
spread
1.99
value
6.9
group Id
OG001
spread
1.27
value
6.8
title
Dysphagia Scale: Week 25 (n=64,124)
categories
measurements
group Id
OG000
spread
1.84
value
6.6
group Id
OG001
spread
1.03
value
5.3
title
Dysphagia Scale: Week 28 (n=47,111)
categories
measurements
group Id
OG000
spread
2.16
value
6.4
group Id
OG001
spread
1.40
value
6.8
title
Dysphagia Scale: Week 31 (n=45,95)
categories
measurements
group Id
OG000
spread
1.44
value
3.9
group Id
OG001
spread
1.51
value
7.5
title
Dysphagia Scale: Week 34 (n=37,87)
denoms
counts
group Id
OG000
value
290
group Id
OG001
value
294
units
Participants
description
The QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms.
dispersion Type
Standard Error
groups
description
Participants received fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles as follows: cisplatin 80 mg/m\^2, IV, on Day 1 and EITHER: 5-FU 800 mg/m\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\^2, tablets, PO, BID from the evening of Day 1 through the morning of Day 15.
id
OG000
title
Fluoropyrimidine/Cisplatin (FP)
description
Participants received trastuzumab plus fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles (except as noted) as follows: trastuzumab 8 mg/kg, IV, on Day 1 (Cycle 1), followed by 6 mg/kg, IV (Cycles 2 onward, administered until disease progression); cisplatin 80 mg/m\^2 IV on Day 1; and EITHER 5-FU 800 mg/m\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\^2 tablets, PO BID from the evening of Day 1 through the morning of Day 15.
id
OG001
title
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)
param Type
MEAN
population Description
FAS; n = number of participants assessed for a specific parameter at a given visit.
reporting Status
POSTED
time Frame
BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
title
EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores
Triangle